TYBR Health

Executive Summary

TYBR Health is a preclinical-stage digital health and AI/ML company developing the B3 GEL™ System, a flowable extracellular matrix (ECM)-based bio-gel barrier designed to prevent post-surgical tissue tethering and adhesions, particularly in tendon and ligament repairs. Post-surgical adhesions are a common complication that impair recovery, leading to pain, reduced mobility, and often requiring revision surgeries. The B3 GEL™ creates a protective, conforming barrier that reduces scar formation, aiming to close the gap between successful surgical repair and full functional recovery. This addresses a significant unmet need, as current anti-adhesion products have limitations in conformability and efficacy. Founded in 2019 and based in Austin, Texas, TYBR Health is leveraging its proprietary ECM technology to potentially improve outcomes and reduce healthcare costs. The global adhesion barrier market is projected to exceed $1 billion, offering a sizable opportunity.

Upcoming Catalysts (preview)

• Q2 2026First-in-human clinical trial initiation for B3 GEL in tendon repair70% success
• Q4 2026FDA 510(k) pre-submission or breakthrough device designation request60% success
• Q3 2026Series A funding round completion80% success